Researchers at Johns Hopkins Kimmel Cancer Center have developed a system that uses differentiated human stem cells to expedite the testing of existing drugs that might work against rare cancers. By transforming human stem cells into an aggressive form of pediatric brain cancer, medulloblastoma, they can be compared to cancer cells already tested against existing drugs.
Eric Raabe, M.D., Ph.D., an assistant professor of oncology at the Johns Hopkins University School of Medicine, and his colleagues create malignant tumors from the stem cells. They then produce a "signature" of gene expression of the tumor that they could compare to similar signatures of cell lines that have been screened and matched with existing drugs. "We wanted to find whether the cells we created matched any of these existing signatures," Raabe explains, "because if they did, then we would have some idea of what kinds of drugs are more or most likely to kill these cells. We didn't have to do the laborious screening to test 100,000 compounds against our own cells."
Johns Hopkins Kimmel Cancer Center’s innovative research demonstrates the integral role stem cells are playing in cutting edge medical care options. By banking their own valuable stem cells, families can ensure that they will have access to these emerging therapies in the near future. To learn more about banking stem cells, please visit StemSave or call 877-783- 6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.